Xingyue Biological Company has been approved to establish a "Postdoctoral Research Workstation"

On November 27, 2015, Zhejiang Xingyue Biotechnology Co., Ltd. received approval from the Zhejiang Provincial Department of Human Resources and Social Security to establish a postdoctoral research station. This provides a better platform for the company to attract more high-level talent and strengthen exchanges and cooperation between enterprises and high-tech talents. Xingyue Biotechnology is also the first unit within the scope of Hangzhou Future Science and Technology City (Haichuang Park) to establish a "postdoctoral workstation".

As a leader in the field of tissue engineering and regenerative medicine, Xingyue Biotech has been dedicated to the research and development of tissue engineering products and regenerative medicine technologies. It has successfully developed the ABioC tissue engineering technology, bringing new hope to patients with intractable orthopedic diseases. Meanwhile, the company's three Class III medical device products have basically been finalized, and it is expected that they will obtain product registration certificates in the next two years and be officially launched onto the market. In recent years, leveraging national, provincial, and municipal major science and technology projects, the company has implemented a number of industry-university-research cooperation projects with universities. While collaborating with partner universities to overcome technical challenges, the company has specifically introduced doctoral research talents and university professors to serve as postdoctoral mentors for the enterprise. The company now boasts a core research and management team consisting of overseas returnees who are academicians of the Chinese Academy of Sciences and leaders of the national "Thousand Talents Plan" entrepreneurship program. Research and development personnel account for about 50% of the total number of employees, and the company has been granted more than 10 product invention patents.

The approval of the establishment of the postdoctoral research station is a testament to the continuous efforts of the Xingyue management team and a recognition of Xingyue's technological innovation and research capabilities in the field of tissue engineering in recent years. Xingyue Biotech has been in the tissue engineering field for five years. With the support and care from governments and leaders at all levels, including provincial, municipal, district, the Future Science and Technology City Management Committee, and sub-districts, Xingyue Biotech's business performance has continuously improved, and the company's scale has grown steadily. In the future, we need to accelerate the industrialization of products, develop high-end biomaterials and practical technologies, and thus require more high-level talents. "Technology" and "talent" are the dual wings for the company's take-off and development, and the postdoctoral research station serves as a crucial carrier for technological innovation and talent cultivation. In the future, the company will attract more freshly graduated doctors to work here, further relying on the postdoctoral research station to carry out research on practical technologies and high-end products. Leveraging the company's existing technology, patents, and product background, we ensure that the researched technologies and products can be industrialized, and through this platform, achieve the transformation and upgrading of products and technologies, creating greater value for the company. At the same time, the postdoctoral research station will establish a cooperative mechanism with postdoctoral mobile stations in universities to jointly cultivate postdoctoral talents. Combining the company's industrialization platform with the theoretical basic research of universities and institutes, we will accelerate the construction of a composite high-level talent team, providing the strongest support for enhancing the company's independent innovation capability and core competitiveness. The establishment of the Xingyue Biotech postdoctoral research station will achieve a "win-win" situation for the personal growth of postdoctoral personnel and the technological progress and innovation of the company. With the joint support of multiple R&D platforms such as the academician workstation, postdoctoral research station, and provincial key enterprise research institute, Xingyue Biotech will surely accelerate the realization of the goal of "regenerative health through technology" and become a leader in the development of China's tissue engineering industry.